Fig. 1From: Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatmentFirst-line treatment PFS of patients in the 1-CRZ group, the 1-PP groupBack to article page